CDKN2A and lung adenocarcinoma: According to the genome analysis of 230 resected lung adenocarcinomas by the Cancer Genome Atlas Research Network, the rate of the loss of p53 function was 63%, and of the inactivation of the RB pathway (such as by the homozygous deletion of CDKN2A and by the amplification of CDK4 and/or CCND1) was 64% [36].